1. 335 Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors. (September 2015) Authors: Garralda, E.; Stathis, A.; Drilon, A.; Boni, V.; Hyman, D.; Calvo, E.; Griguolo, G.; Makker, V.; Doger, B.; Canziani, L.; Varghese, A.M.; Jimenez, E.; Luque, J.; Soto-Matos, A.; Szyldergemajn, S.; Sessa, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. (December 2016) Authors: Drilon, A.; Marwan, F.; Fu, S.; Patel, M.R.; Olszanski, A.J.; Lockhart, A.C.; Liu, S.V.; Bazhenova, L.; Seery, T.; Nikolinakos, P.; Patel, R.; Oliver, J.W.; Multani, P.S.; Wang, D. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside. (December 2016) Authors: Ho, A.; Wei, G.; Maneval, E.C.; Esquibel, V.; Berger, M.F.; Haque, S.; Patel, R.; Walsh, C.; Hornby, Z.; Multani, P.; Li, G.; Drilon, A. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC). (October 2022) Authors: Cho, B.C.; Lin, J.; Camidge, D.R.; Velcheti, V.; Solomon, B.; Lu, S.; Lee, K.H.; Kim, S.W.; Kao, S.; Diadziuskzko, R.; Beg, M.; Nagasaka, M.; Felip, E.; Besse, B.; Springfeld, C.; Popat, S.; Wolf, J.; Trone, D.; Stopatschinskaja, S.; Drilon, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors. (October 2022) Authors: Drilon, A.; Besse, B.; Camidge, D.R.; Ou, S.H.I.; Gadgeel, S.M.; Johnson, M.L.; Calles, A.; de Miguel, M.J.; Spira, A.I.; Felip, E.; Lopes, G.; van der Wekken, A.J.; Elamin, Y.Y.; Green, J.; Sun, Y.; Soglia, J.; Zhu, V.W.; Lin, J.J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits resistant NTRK kinase domain mutants. (December 2016) Authors: Drilon, A.; Hofmann, N.; Flynn, D.; Smith, B.; Davare, M. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). (October 2022) Authors: Besse, B.; Springfeld, C.; Baik, C.; Hervieu, A.; Solomon, B.; Moreno, V.; Bazhenova, L.; Goto, K.; Kim, Y.C.; Lu, S.; Sun, M.; Trone, D.; Thamake, S.; Cho, B.C.; de Langen, A.; Popat, S.; Wolf, J.; Moro-Sibilot, D.; Fang, J.; Drilon, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗